POT1 Tumor Predisposition Syndrome: Disease Characteristics Research Report

Scope. This report prioritizes evidence available through 2024. POT1 tumor predisposition syndrome (POT1-TPD) remains exceptionally rare; penetrance estimates and many proposed tumor associations are not yet reliable. Accordingly, the report separates the well-supported core phenotype from hypothesis-generating case reports and small cohorts.

The principal evidence is summarized below.

Table: This table summarizes the most actionable current evidence for POT1 tumor predisposition syndrome, highlighting what is well-supported versus still uncertain. It is useful as a compact reference for identifiers, diagnosis, mechanism, surveillance, and the strongest human and model-system data.

1. Disease information

Definition

POT1-TPD is a Mendelian, autosomal-dominant hereditary cancer-predisposition syndrome caused by a heterozygous germline pathogenic or likely pathogenic variant in POT1, which encodes a single-stranded telomeric-DNA-binding component of shelterin. The best-supported tumors are multiple cutaneous melanomas, chronic lymphocytic leukemia (CLL), angiosarcoma—particularly cardiac angiosarcoma—and glioma. Most cancers occur in adulthood, although melanoma has been reported from age 15 onward. Penetrance and the complete tumor spectrum remain unknown. (ardinger1993pot1tumorpredisposition pages 1-3, freitas2024pot1tumourpredisposition pages 1-2)

Identifiers and synonyms

• MONDO: MONDO:0014368, tumor predisposition syndrome 3.
• OMIM phenotype: 615848, commonly called tumor predisposition syndrome 3.
• Gene: POT1, protection of telomeres 1; Ensembl ENSG00000128513; chromosome 7q31.33. Open Targets gives POT1–MONDO:0014368 an association score of approximately 0.816, supported by multiple genetic studies. (OpenTargets Search: POT1 tumor predisposition syndrome-POT1, freitas2024pot1tumourpredisposition pages 1-2)
• Common names: POT1 tumor predisposition; POT1 tumor predisposition syndrome; POT1-TPD; POT1-associated hereditary cancer syndrome; tumor predisposition syndrome 3.
• Orphanet: No confidently verified syndrome-specific ORPHA number was recovered.
• ICD-10/ICD-11 and MeSH: No unique POT1-TPD code/descriptor was identified. Coding generally uses a hereditary cancer-susceptibility code plus codes for the particular neoplasm and genetic finding.

The evidence is aggregated at the disease/family level from GeneReviews, pedigrees, cancer cohorts, ClinVar-like variant resources, and experimental studies—not derived from a single EHR population. Individual case reports contribute mainly to proposed expansion of the phenotype.

2. Etiology

Causal factor

The necessary inherited lesion is a heterozygous germline pathogenic/likely pathogenic POT1 variant. Reported disease-associated classes include missense, nonsense, frameshift, and splice-site variants. Variants may impair binding of POT1 to telomeric DNA through its N-terminal OB folds or disrupt its C-terminal interaction with ACD/TPP1, thereby altering shelterin function. Loss of heterozygosity is not consistently required; several engineered and clinical observations support a dominant-negative or haploinsufficient effect, depending on the allele. (kim2021cancer‐associatedpot1mutations pages 1-2, speedy2016germlinemutations pages 1-5, calvete2015amutationin pages 1-2)

Genetic risk factors

Foundational human studies include:

• Familial melanoma cohorts identified POT1 variants in 4/105 (3.8%) CDKN2A/CDK4-negative families and 7/56 (12.5%) Italian families. Reported alleles included p.Tyr89Cys, p.Gln94Glu, p.Arg273Leu, c.1687-1G>A, p.Ser270Asn, p.Arg137His, and p.Gln623His. The landmark 2014 melanoma papers are indexed under PMIDs 24686846 and 24686849. (OpenTargets Search: POT1 tumor predisposition syndrome-POT1, wu2020roleofpot1 pages 5-8)
• In familial glioma, POT1 p.Gly95Cys and p.Glu450Ter were detected in 2/55 families (3.6%); the implicated families notably included oligodendroglioma. (webster2023germlinepot1gene pages 16-19, wu2020roleofpot1 pages 5-8)
• Whole-exome sequencing of 66 CLL families identified four families with co-segregating POT1 variants: p.Tyr36Cys, p.Gln376Arg, p.Gln358SerfsTer13, and c.1164-1G>A. In 1,083 cases and 5,854 controls, p.Gln376Arg—global minor-allele frequency 0.0005—conferred an estimated 3.61-fold CLL risk (P=0.009). Published online August 15, 2016; DOI: 10.1182/blood-2016-01-695692. The abstract states: “loss-of-function mutations in POT1 co-segregated with CLL.” (speedy2016germlinemutations pages 1-5)
• POT1 p.Arg117Cys was found in several TP53-negative Li–Fraumeni-like families containing cardiac angiosarcoma. It was absent from 1,520 Spanish controls and observed once among 121,324 ExAC alleles. Published September 25, 2015; DOI: 10.1038/ncomms9383. (calvete2015amutationin pages 1-2)

Modifier genes: No validated modifier gene is established. Somatic BRAF, NRAS, or KIT alterations can cooperate in melanocytic lesions, and KDR/VEGF-pathway alterations have been reported in cardiac angiosarcoma, but these are tumor drivers rather than proven germline modifiers.

Environmental and protective factors

No exposure causes the inherited syndrome. UV radiation is an established melanoma risk factor generally, but its specific contribution to POT1-associated melanoma is unresolved; one review notes no demonstrated POT1-specific UV effect, while molecular analysis of p.Ile78Thr-associated lesions found a UV mutational signature. Sun avoidance therefore remains prudent despite uncertain gene-specific interaction. (ardinger1993pot1tumorpredispositiona pages 5-8, ardinger1993pot1tumorpredisposition pages 5-8)

No genetic protective allele, diet, medication, or lifestyle intervention has been shown to neutralize POT1-TPD risk. Avoidance of tanning beds, unprotected ultraviolet exposure, tobacco, and unnecessary ionizing radiation is reasonable risk reduction, not proven syndrome-specific prevention.

3. Phenotypes

POT1-TPD generally has no congenital dysmorphism or obligate non-neoplastic phenotype. The manifestations are tumors and their site-specific symptoms.

• Cutaneous melanoma: Multiple primary melanomas may occur; reported onset 15–80 years, generally adult, with variable severity and recurrence. Suggested HPO: HP:0002861 Melanoma, HP:0008069 Neoplasm of the skin, and multiple primary neoplasm where locally supported. Functional and quality-of-life effects depend on stage, surgery, disfigurement, metastatic disease, and surveillance burden. (ardinger1993pot1tumorpredisposition pages 1-3)
• CLL: Usually adult/late-onset; may be asymptomatic lymphocytosis or progressive nodal, marrow, and systemic disease. Suggested HPO: HP:0001909 Leukemia, HP:0002716 Lymphadenopathy, HP:0004313 Decreased circulating antibody level, HP:0001873 Thrombocytopenia, and HP:0001923 Reticulocytopenia/anemia terms as documented clinically. POT1 variants have been reported in approximately 3.5% of CLL in one summarized dataset, but that figure includes tumor-level observations and is not the prevalence of germline POT1-TPD. (feldman1993pot1tumorpredisposition pages 5-7)
• Angiosarcoma: Particularly cardiac, but breast and other soft-tissue sites have been reported. Severity is often high and progression can be rapid. Suggested HPO: HP:0030448 Angiosarcoma where available, HP:0003002 Breast carcinoma, and site-specific cardiac neoplasm terms. Cardiac disease can cause dyspnea, arrhythmia, obstruction, effusion, heart failure, or embolic/metastatic complications.
• Glioma: Histologies include oligodendroglial and other diffuse gliomas; symptoms depend on site and include headache, seizure, focal weakness, behavior/personality change, vomiting, or impaired balance. Suggested HPO: HP:0009733 Glioma, HP:0001250 Seizure, HP:0002315 Headache, and HP:0004372 Reduced consciousness when present. Pediatric CNS-tumor guidance emphasizes that approximately 15–21% of childhood CNS tumors overall are associated with predisposition syndromes, but this is not a POT1-specific frequency. (webster2023germlinepot1gene pages 16-19, hansford2024updateoncancer pages 1-2)

The proposed expanded spectrum includes other sarcomas, papillary thyroid carcinoma, hematologic malignancies, colorectal cancer, prostate cancer, breast cancer, lung cancer, renal cancer, and GIST. These should be annotated as limited or emerging evidence, not as established penetrant features. A 2024 series of three multigenerational families tested 37 people—19 women and 18 men, median age 46 years—and found the familial POT1 variant in 22; additional sarcomas, papillary thyroid cancer, early-onset prostate cancer, and leukemia were observed. DOI: 10.1038/s41431-024-01611-0, published online June 5, 2024. (freitas2024pot1tumourpredisposition pages 1-2)

No POT1-specific EQ-5D, SF-36, PROMIS, disability, or behavioral-phenotype studies were identified.

4. Genetic and molecular information

Gene and protein

• POT1, chromosome 7q31.33; approved name protection of telomeres 1.
• Protein function: binds the 3′ single-stranded TTAGGG telomeric overhang; interacts with ACD/TPP1; limits inappropriate RPA–ATR damage signaling and regulates telomerase access and telomere length. (freitas2024pot1tumourpredisposition pages 1-2, kim2021cancer‐associatedpot1mutations pages 1-2)
• Suggested GO cellular components: telomere, nuclear chromosome telomeric region, shelterin complex, nucleus.
• Suggested GO functions/processes: single-stranded telomeric DNA binding, telomere capping, telomere maintenance, negative regulation of telomerase activity, negative regulation of DNA-damage response, and chromosome-end protection.

Representative germline variants

• p.Arg117Cys: missense, OB-fold region; reduced telomere-bound POT1, long and fragile telomeres; dominant-negative behavior in the Pot1a knock-in model; associated particularly with cardiac angiosarcoma families. (calvete2015amutationin pages 1-2, martinez2022amousemodel pages 1-2)
• p.Tyr36Cys: missense affecting telomeric-overhang interaction.
• p.Gln376Arg, p.Gln358SerfsTer13, c.1164-1G>A: affect or are predicted to affect the POT1–ACD interaction; familial CLL evidence. (speedy2016germlinemutations pages 1-5)
• p.Gly95Cys, p.Glu450Ter, p.Asp617GlufsTer9: reported in glioma families. (andreotti2024germlinepot1variants pages 5-6)
• p.Ile78Thr/c.233T>C, p.Gln623His, p.Ser270Asn, p.Arg137His: recurrent familial melanoma-associated alleles.
• The 2024 family study examined c.349C>T, c.233T>C, and c.818G>A. (freitas2024pot1tumourpredisposition pages 1-2)

Pathogenicity must be assessed per ACMG/AMP criteria using population rarity, segregation, phenotype specificity, RNA evidence for splice variants, functional assays, and curated clinical evidence. A VUS does not establish POT1-TPD and should not drive predictive testing or irreversible management. Many reported POT1 substitutions remain VUS because segregation and standardized functional evidence are lacking. (ardinger1993pot1tumorpredisposition pages 1-3, andreotti2024germlinepot1variants pages 8-9)

Disease-causing alleles are expected to be very rare in gnomAD; no single carrier-frequency estimate is validated. Somatic POT1 variants also occur in tumors and can suggest germline testing, but tumor-only detection does not prove constitutional origin. Constitutional confirmation should use blood or saliva, and cultured fibroblasts when hematologic malignancy or clonal hematopoiesis could confound blood testing.

No recurrent syndrome-defining chromosomal rearrangement, methylation signature, or epigenetic defect is established.

5. Environmental information

• UV exposure: relevant to melanoma prevention, but POT1-specific effect size is unknown.
• Ionizing radiation: not known to cause POT1-TPD; unnecessary diagnostic radiation is often avoided because lifelong surveillance is required and MRI/ultrasonography can reduce cumulative exposure. (ardinger1993pot1tumorpredisposition pages 5-8)
• Smoking, alcohol, diet, exercise, occupational toxins, pollution: no POT1-specific quantitative evidence.
• Infectious agents: none causes or triggers the syndrome. Infection can complicate CLL-related immune dysfunction but is downstream, not etiologic.

6. Mechanism and pathophysiology

Ordered causal chain

1. A heterozygous germline pathogenic POT1 variant leads to reduced or altered POT1 binding to telomeric single-stranded DNA and/or impaired interaction with ACD/TPP1.
2. Altered POT1–shelterin function leads to defective control of telomerase access, telomeric-overhang processing, and—in a variant/context-dependent manner—RPA exclusion and ATR signaling. (kim2021cancer‐associatedpot1mutations pages 1-2, speedy2016germlinemutations pages 1-5)
3. This commonly results in progressive telomere elongation; some alleles also result in telomere fragility and chromosome instability. (calvete2015amutationin pages 1-2)
4. Long telomeres lead to delayed replicative senescence and an extended proliferative lifespan, increasing the time during which a premalignant clone can acquire cooperating mutations. Human stem-cell work supports this step without requiring overt telomeric damage. (kim2021cancer‐associatedpot1mutations pages 1-2)
5. Mechanistic branch A: in telomerase-positive precursor cells, increased telomerase-mediated extension leads to sustained clonal expansion and malignant transformation.
6. Mechanistic branch B: where telomeric structures accumulate, unresolved G-quadruplexes lead to RPA binding and ATR-dependent DNA-damage signaling, which can recruit telomerase and further hyper-elongate telomeres; this branch is demonstrated in Pot1b-null mouse sarcomas and inferred, not proven universally, in human carriers. (takasugi2023pot1b−−tumors pages 1-2)
7. Tissue-specific cooperating drivers then lead to melanocytic, B-cell, glial, or endothelial malignancy; why these lineages are preferentially affected remains incompletely understood.
8. Tumor growth, invasion, hemorrhage, marrow replacement, or CNS mass effect then results in the clinical manifestations of melanoma, CLL, angiosarcoma, or glioma.

Experimental support

CRISPR/Cas9-engineered human embryonic and hematopoietic stem cells carrying cancer-associated POT1 variants showed telomere elongation but no overt telomere-damage response or competitive disadvantage. The authors concluded that these variants may be selected because they “elongate telomeres and extend the proliferative capacity” of incipient cancer cells. Published May 2, 2021; DOI: 10.15252/embj.2020107346. (kim2021cancer‐associatedpot1mutations pages 1-2)

In serially transplanted Pot1b-null mouse sarcomas, early tumors had short telomeres but late-generation tumors developed markedly hyper-elongated telomeres. Telomeric G-quadruplexes were recognized by RPA, activating ATR and telomerase recruitment. Published August 10, 2023; DOI: 10.1093/nar/gkad648. (takasugi2023pot1b−−tumors pages 1-2)

Suggested GO terms include telomere maintenance, telomerase-mediated telomere elongation, DNA-damage response, ATR signaling, chromosome organization, replicative senescence, cell-population proliferation, and regulation of apoptosis. Suggested cell types include melanocyte (CL:0000148), B lymphocyte (CL:0000236), endothelial cell (CL:0000115), glial lineage cells, hematopoietic stem cell, and embryonic stem cell. No reproducible POT1-TPD-specific metabolomic, lipidomic, proteomic, single-cell, spatial-transcriptomic, or methylation signature has been established.

7. Anatomical structures affected

Primary sites reflect the tumor spectrum:

• Skin/melanocytic system: epidermis and dermal–epidermal melanocytic compartment; UBERON suggestions: skin of body, epidermis.
• Hematolymphoid system: blood, bone marrow, lymph nodes, spleen; UBERON: blood, bone marrow, lymph node, spleen.
• Cardiovascular/mesenchymal system: cardiac endothelium and other vascular/soft-tissue sites; UBERON: heart, blood vessel, connective tissue.
• Central nervous system: brain and glial tissues; UBERON: brain, cerebral hemisphere, white matter as tumor location warrants.

At the subcellular level, the critical structures are the nucleus, chromosome ends/telomeres, single-stranded telomeric overhang, and shelterin complex. Lateralization is tumor-specific; the syndrome has no characteristic unilateral or bilateral pattern.

8. Temporal development

The genotype is constitutional from conception, but the phenotype is usually insidious and age-dependent. Most tumors occur in adulthood; the earliest reported first primary was at age 15. Surveillance is commonly started at age 18 or 2–5 years before the earliest familial diagnosis. (ardinger1993pot1tumorpredisposition pages 1-3, freitas2024pot1tumourpredisposition pages 1-2)

There is no syndrome-level staging system. Each tumor follows its standard AJCC/WHO staging and grading. The syndrome is lifelong; carriers can develop metachronous multiple primary tumors. Remission is treatment-induced and tumor-specific. No evidence supports spontaneous syndrome remission, anticipation, or a defined critical developmental window beyond age-based screening.

9. Inheritance and population

• Inheritance: autosomal dominant; each child of a heterozygous carrier has a 50% chance of inheriting the variant. (ardinger1993pot1tumorpredisposition pages 1-3)
• Penetrance: incomplete or at least age-dependent and currently unknown. Published families are highly ascertained and unsuitable for unbiased lifetime-risk estimates. (andreotti2024germlinepot1variants pages 8-9, freitas2024pot1tumourpredisposition pages 1-2)
• Expressivity: markedly variable, including unaffected adult carriers and carriers with multiple primary cancers.
• De novo variation: possible, but its proportion is unknown.
• Mosaicism/germline mosaicism: no established frequency.
• Anticipation: not demonstrated.
• Consanguinity: not relevant to the dominant inheritance pattern.
• Founder effects: p.Ile78Thr/c.233T>C has recurred in melanoma pedigrees of Jewish/Ashkenazi ancestry, suggesting a founder allele; founder-associated enrichment should not be generalized to all populations.
• Prevalence/incidence: no defensible cases-per-100,000 estimate exists. Only several hundred probands had reportedly been tested by 2024. (freitas2024pot1tumourpredisposition pages 1-2)
• Sex ratio: no established sex bias. The 2024 family cohort was 51.4% female, but this is not a population estimate. (freitas2024pot1tumourpredisposition pages 1-2)

10. Diagnostics

Clinical suspicion

Consider POT1-TPD in a person with:

1. Multiple primary cutaneous melanomas;
2. A core POT1 tumor plus a first- or second-degree relative with melanoma, CLL, angiosarcoma, or glioma;
3. Cardiac angiosarcoma or a TP53-negative Li–Fraumeni-like pedigree;
4. Familial oligodendroglioma/glioma; or
5. A potentially pathogenic POT1 alteration identified by tumor sequencing. (freitas2024pot1tumourpredisposition pages 1-2)

Molecular confirmation

Diagnosis requires a heterozygous germline pathogenic/likely pathogenic POT1 variant. Appropriate methods are:

• hereditary melanoma, brain-tumor, hematologic-malignancy, sarcoma, or broad hereditary-cancer multigene panels containing POT1;
• POT1 sequence analysis with deletion/duplication analysis;
• targeted familial-variant testing for relatives;
• WES/WGS when panel testing is negative but suspicion remains, particularly for unusual splice, structural, or noncoding lesions.

CMA, karyotyping, FISH, mitochondrial testing, and repeat-expansion testing are not routine diagnostic approaches. RNA studies may clarify splice variants. Telomere-length measurement can support functional investigation but is not sufficiently standardized or specific to diagnose POT1-TPD. (andreotti2024germlinepot1variants pages 8-9, speedy2016germlinemutations pages 1-5)

Surveillance tests

Expert-opinion practice includes:

• full-body dermatologic examination at least every six months from age 18; every 3–6 months for multiple atypical nevi or personal/family melanoma history;
• annual complete blood count with differential and clinical examination of lymph nodes;
• annual comprehensive physical examination;
• annual whole-body MRI in Li–Fraumeni/Li–Fraumeni-like families and individualized 1–2-year MRI in other selected carriers;
• brain MRI every 1–2 years where family history supports glioma risk. (ardinger1993pot1tumorpredisposition pages 1-3, ardinger1993pot1tumorpredisposition pages 5-8, freitas2024pot1tumourpredisposition pages 1-2)

There are no universally validated biochemical biomarkers, liquid-biopsy tests, or syndrome-specific histopathologic criteria. Differential diagnoses include CDKN2A/CDK4 familial melanoma, BAP1 tumor-predisposition syndrome, Li–Fraumeni syndrome, hereditary retinoblastoma, constitutional mismatch-repair deficiency/Lynch-spectrum syndromes, DICER1 syndrome, NF1/NF2, and other shelterin/telomere-gene disorders. Unlike classic short-telomere syndromes, POT1-TPD is generally associated with long telomeres and lacks obligate marrow failure, pulmonary fibrosis, or mucocutaneous features.

11. Outcome and prognosis

No POT1-TPD-specific overall survival, life expectancy, 5-year survival, mortality rate, disability burden, or quality-of-life dataset exists. Prognosis is dominated by tumor type, anatomic site, stage, grade, treatment response, and the occurrence of multiple primaries.

Historical cardiac-angiosarcoma data cited in the p.Arg117Cys study describe a poor prognosis: sporadic angiosarcoma 5-year survival of approximately 14%, and mean survival of four months in the cited familial cases. These values are old, small-series estimates and should not be treated as a modern POT1-carrier survival estimate. (calvete2015amutationin pages 1-2)

Potential prognostic factors include early detection, metastatic status, cardiac involvement, glioma grade/molecular class, CLL cytogenetics and stage, melanoma Breslow depth, and somatic driver profile. Telomere length or POT1 genotype is not yet a validated clinical prognostic biomarker.

12. Treatment

There is no approved POT1-TPD-specific drug, gene therapy, RNA therapy, or preventive telomere-directed treatment. Tumors are treated according to standard histology- and stage-specific guidelines. (freitas2024pot1tumourpredisposition pages 1-2)

• Melanoma: surgical excision; sentinel-node procedures when indicated; immune-checkpoint inhibitors and BRAF/MEK inhibition according to somatic genotype and stage. Suggested NCIt concepts: melanoma surgery, pembrolizumab, nivolumab, ipilimumab, dabrafenib, trametinib.
• CLL: observation for asymptomatic early disease; BTK inhibitors, venetoclax-based regimens, anti-CD20 antibodies, or other guideline-based combinations when treatment criteria are met. Suggested NCIt: ibrutinib/acalabrutinib/zanubrutinib, venetoclax, obinutuzumab.
• Glioma: maximal safe resection, radiotherapy, temozolomide, tumor-specific targeted therapy, and supportive neuro-oncology care as appropriate.
• Angiosarcoma: resection when feasible, systemic chemotherapy and/or radiotherapy; cardiac disease requires multidisciplinary sarcoma, cardiothoracic, and transplant expertise.

Cell-line observations suggest that long telomeres/POT1 upregulation may influence radiotherapy resistance and motivate POT1 or telomerase inhibition research, but this is not clinically validated. Germline status presently guides surveillance and family counseling rather than selection of an approved POT1-targeted agent. (freitas2024pot1tumourpredisposition pages 1-2)

A ClinicalTrials.gov-oriented search found no POT1-TPD-specific interventional trial. Enrollment should therefore be based on the patient’s tumor histology and actionable somatic alterations rather than the syndrome alone.

13. Prevention

• Primary prevention: the germline state cannot currently be prevented after conception. Counsel on sun protection, avoidance of tanning beds, smoking cessation, healthy weight, and minimizing unnecessary radiation; only photoprotection has an obvious tumor-specific rationale, and no POT1-specific risk reduction has been quantified.
• Secondary prevention: cascade genetic testing and structured skin, hematologic, physical, and MRI surveillance are the principal real-world interventions. (ardinger1993pot1tumorpredisposition pages 1-3, ardinger1993pot1tumorpredisposition pages 5-8)
• Tertiary prevention: tumor-specific follow-up to detect recurrence, second primaries, therapy complications, and CLL-associated infection or immune dysfunction.
• Reproductive options: preimplantation genetic testing for monogenic disease and prenatal diagnosis are technically possible once a familial pathogenic variant is known; these require nondirective genetic counseling.
• Testing minors: generally deferred until surveillance would change, but testing before 18 can be considered when a family contains childhood or adolescent cancers. (ardinger1993pot1tumorpredisposition pages 5-8)
• Vaccination/prophylactic medication: no syndrome-specific vaccine or chemoprevention exists.

14. Other species and natural disease

No well-established naturally occurring veterinary syndrome directly equivalent to human POT1-TPD was identified, and no breed-specific VBO association or zoonotic relevance applies. POT1 and telomere-end protection are evolutionarily conserved across eukaryotes, but rodents possess Pot1a and Pot1b, partitioning functions performed by the single human POT1 protein. This limits direct extrapolation from knockout phenotypes. (takasugi2023pot1b−−tumors pages 1-2)

Suggested taxa: human NCBI Taxon 9606; laboratory mouse NCBI Taxon 10090. The condition is inherited, not transmissible or zoonotic.

15. Model organisms and experimental systems

Human cellular models

CRISPR/Cas9-engineered human embryonic stem cells and hematopoietic stem cells carrying heterozygous cancer-associated POT1 variants model the clinically relevant allelic state. They reproduce telomere elongation and extended proliferative potential but, for the tested alleles, not strong telomere-damage signaling. This demonstrates that elongation can be uncoupled from overt deprotection. (kim2021cancer‐associatedpot1mutations pages 1-2)

Pot1a p.Arg117Cys knock-in mouse

Heterozygous Pot1a+/R117C mice and mouse embryonic fibroblasts have longer telomeres than wild-type controls; elongation disappears in a Tert-null background, showing telomerase dependence. The allele exerts dominant-negative effects, and mice spontaneously develop a high incidence of angiosarcoma, including cardiac angiosarcoma, with long telomeres in endothelial cells and tumors. Published June 21, 2022; DOI: 10.1371/journal.pgen.1010260. The abstract states that the model “constitutes a useful tool to understand human cancers initiated by POT1 mutations.” (martinez2022amousemodel pages 1-2)

Pot1b-null sarcoma model

Serial transplantation of Pot1b-null sarcomas in immunodeficient mice models adaptive telomere hyper-elongation and revealed the G-quadruplex–RPA–ATR–telomerase mechanism. It is valuable for mechanistic and preclinical telomere studies but does not reproduce a heterozygous human germline syndrome or its complete tumor spectrum. (takasugi2023pot1b−−tumors pages 1-2)

No validated zebrafish, Drosophila, C. elegans, canine, feline, organoid, or patient-derived iPSC model was identified specifically for POT1-TPD.

Evidence appraisal and current expert interpretation

The most defensible knowledge-base representation is: POT1-TPD is a rare, autosomal-dominant, long-telomere cancer-predisposition syndrome with established associations to melanoma and meaningful evidence for CLL, angiosarcoma, and glioma, but unknown penetrance and incompletely defined variant-specific risks. The 2024 critical review cautioned that many non-core associations rely on single cases, incompletely classified variants, absent segregation, or nonstandardized telomere assays. It advised against automatically applying maximal Li–Fraumeni-style surveillance to every carrier, except where variant and family history—especially sarcoma history—justify it. (andreotti2024germlinepot1variants pages 8-9, andreotti2024germlinepot1variants pages 5-6)

Consequently, surveillance should be individualized in a multidisciplinary hereditary-cancer clinic, and broad tumor associations should be upgraded only after replicated segregation, robust functional validation, and unbiased carrier cohorts provide quantitative penetrance estimates.

References

1. (OpenTargets Search: POT1 tumor predisposition syndrome-POT1): Open Targets Query (POT1 tumor predisposition syndrome-POT1, 9 results). Buniello, A. et al. (2025). Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery. Nucleic Acids Research.

2. (ardinger1993pot1tumorpredisposition pages 1-3): HH Ardinger and RA Pagon. Pot1 tumor predisposition. Unknown journal, 1993.

3. (freitas2024pot1tumourpredisposition pages 1-2): Marta Baptista Freitas, Laurence Desmyter, Cindy Badoer, Guillaume Smits, Isabelle Vandernoot, and Daphné t´Kint de Roodenbeke. Pot1 tumour predisposition: a broader spectrum of associated malignancies and proposal for additional screening program. European Journal of Human Genetics, 32:980-986, Jun 2024. URL: https://doi.org/10.1038/s41431-024-01611-0, doi:10.1038/s41431-024-01611-0. This article has 18 citations and is from a domain leading peer-reviewed journal.

4. (andreotti2024germlinepot1variants pages 8-9): Virginia Andreotti, Irene Vanni, Lorenza Pastorino, Paola Ghiorzo, and William Bruno. Germline pot1 variants: a critical perspective on pot1 tumor predisposition syndrome. Jan 2024. URL: https://doi.org/10.3390/genes15010104, doi:10.3390/genes15010104. This article has 9 citations.

5. (speedy2016germlinemutations pages 1-5): Helen E. Speedy, Ben Kinnersley, Daniel Chubb, Peter Broderick, Philip J. Law, Kevin Litchfield, Sandrine Jayne, Martin J. S. Dyer, Claire Dearden, George A. Follows, Daniel Catovsky, and Richard S. Houlston. Germ line mutations in shelterin complex genes are associated with familial chronic lymphocytic leukemia. Blood, 128 19:2319-2326, Nov 2016. URL: https://doi.org/10.1182/blood-2016-01-695692, doi:10.1182/blood-2016-01-695692. This article has 170 citations and is from a highest quality peer-reviewed journal.

6. (ardinger1993pot1tumorpredispositiona pages 1-3): HH Ardinger and RA Pagon. Pot1 tumor predisposition. Unknown journal, 1993.

7. (kim2021cancer‐associatedpot1mutations pages 1-2): Won‐Tae Kim, Kelsey Hennick, Joshua Johnson, Brendan Finnerty, Seunga Choo, Sarah B Short, Casey Drubin, Ryan Forster, Mary L McMaster, and Dirk Hockemeyer. Cancer‐associated pot1 mutations lead to telomere elongation without induction of a dna damage response. The EMBO Journal, May 2021. URL: https://doi.org/10.15252/embj.2020107346, doi:10.15252/embj.2020107346. This article has 64 citations.

8. (takasugi2023pot1b−−tumors pages 1-2): Taylor Takasugi, Peili Gu, Fengshan Liang, Isabelle Staco, and Sandy Chang. Pot1b −/− tumors activate g-quadruplex-induced dna damage to promote telomere hyper-elongation. Nucleic Acids Research, 51:9227-9247, Aug 2023. URL: https://doi.org/10.1093/nar/gkad648, doi:10.1093/nar/gkad648. This article has 15 citations and is from a highest quality peer-reviewed journal.

9. (calvete2015amutationin pages 1-2): Oriol Calvete, Paula Martinez, Pablo Garcia-Pavia, Carlos Benitez-Buelga, Beatriz Paumard-Hernández, Victoria Fernandez, Fernando Dominguez, Clara Salas, Nuria Romero-Laorden, Jesus Garcia-Donas, Jaime Carrillo, Rosario Perona, Juan Carlos Triviño, Raquel Andrés, Juana María Cano, Bárbara Rivera, Luis Alonso-Pulpon, Fernando Setien, Manel Esteller, Sandra Rodriguez-Perales, Gaelle Bougeard, Tierry Frebourg, Miguel Urioste, Maria A. Blasco, and Javier Benítez. A mutation in the pot1 gene is responsible for cardiac angiosarcoma in tp53-negative li–fraumeni-like families. Nature Communications, Sep 2015. URL: https://doi.org/10.1038/ncomms9383, doi:10.1038/ncomms9383. This article has 220 citations and is from a highest quality peer-reviewed journal.

10. (martinez2022amousemodel pages 1-2): Paula Martínez, Raúl Sánchez-Vázquez, Iole Ferrara-Romeo, Rosa Serrano, Juana M. Flores, and Maria A. Blasco. A mouse model for li-fraumeni-like syndrome with cardiac angiosarcomas associated to pot1 mutations. Jun 2022. URL: https://doi.org/10.1371/journal.pgen.1010260, doi:10.1371/journal.pgen.1010260. This article has 7 citations and is from a domain leading peer-reviewed journal.

11. (ardinger1993pot1tumorpredisposition pages 5-8): HH Ardinger and RA Pagon. Pot1 tumor predisposition. Unknown journal, 1993.

12. (hansford2024updateoncancer pages 1-2): Jordan R. Hansford, Anirban Das, Rose B. McGee, Yoshiko Nakano, Jack Brzezinski, Sarah R. Scollon, Surya P. Rednam, Jaclyn Schienda, Orli Michaeli, Sun Young Kim, Mary-Louise C. Greer, Rosanna Weksberg, Douglas R. Stewart, William D. Foulkes, Uri Tabori, Kristian W. Pajtler, Stefan M. Pfister, Garrett M. Brodeur, and Junne Kamihara. Update on cancer predisposition syndromes and surveillance guidelines for childhood brain tumors. Clinical cancer research : an official journal of the American Association for Cancer Research, 30:2342-2350, Apr 2024. URL: https://doi.org/10.1158/1078-0432.ccr-23-4033, doi:10.1158/1078-0432.ccr-23-4033. This article has 70 citations.

13. (wu2020roleofpot1 pages 5-8): Yangxiu Wu, Rebecca C. Poulos, and Roger R. Reddel. Role of pot1 in human cancer. Cancers, 12:2739, Sep 2020. URL: https://doi.org/10.3390/cancers12102739, doi:10.3390/cancers12102739. This article has 80 citations.

14. (webster2023germlinepot1gene pages 16-19): MD Webster. Germline pot1 gene variants in a clinical and pan-cancer cohort. Unknown journal, 2023.

15. (ardinger1993pot1tumorpredispositiona pages 5-8): HH Ardinger and RA Pagon. Pot1 tumor predisposition. Unknown journal, 1993.

16. (feldman1993pot1tumorpredisposition pages 5-7): J Feldman and GM Mirzaa. Pot1 tumor predisposition. Unknown journal, 1993.

17. (andreotti2024germlinepot1variants pages 5-6): Virginia Andreotti, Irene Vanni, Lorenza Pastorino, Paola Ghiorzo, and William Bruno. Germline pot1 variants: a critical perspective on pot1 tumor predisposition syndrome. Jan 2024. URL: https://doi.org/10.3390/genes15010104, doi:10.3390/genes15010104. This article has 9 citations.

Artifacts

• Edison artifact artifact-00

Reference Validation

Checked with linkml-reference-validator 0.2.1.

All extracted references resolved successfully.

Term Validation

Checked with linkml-term-validator 0.4.5, through the ols: adapter.

Every term resolved, and every label the report gave matched.